The FDA's safety concerns directly impact Geron's potential revenue and market trust in its leading drug, imetelstat. This negative sentiment is likely to affect the stock's short-term performance negatively, as evidenced by the significant drop in stock price and high trading volume. However, the bullish analyst ratings and significant potential upside suggest that the long-term outlook might still be positive, depending on how Geron addresses these concerns.